Findings on Type 2 Diabetes from L. Jacob and Colleagues Provide New Insights (Prescription Patterns and the Cost of Antihyperglycemic Drugs in…

Findings on Type 2 Diabetes from L. Jacob and Colleagues Provide New Insights (Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Current study results on Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes have been published. According to news reporting originating from Lyon, France, by VerticalNews correspondents, research stated, "The goals were to analyze prescription patterns and the cost of antihyperglycemic drugs in patients with type 2 diabetes (T2DM) treated in Germany in 2015. This study included 36382 patients aged 40 years or over treated in general practices (GPs) and diabetologist practices who were diagnosed with T2DM in 2015."

Our news editors obtained a quote from the research, "Nine different families of antihyperglycemic therapy were included in the analysis. Demographic data included age, gender, and type of health insurance coverage. Clinical data included HbA1c level, body mass index (BMI), and the number of T2DM complications. The annual antihyperglycemic treatment cost per patient was calculated based on pharmacy retail prices. The multivariate regression analysis was fitted to estimate the adjusted treatment cost differences. The percentage of T2DM patients receiving antihyperglycemic treatments was 87.6. This share was slightly higher in men than in women (89.1% vs 86.0%). Interestingly, the share of people treated with antihyperglycemic drugs decreased with age yet increased with HbA1c levels, BMI, and the number of complications. The average annual cost of antihyperglycemic drugs amounted to ?498. It was significantly higher in men than in women (difference of ?22). It was also significantly higher in individuals with private health insurance coverage than in people with public health insurance coverage (difference of ?153). The annual cost decreased with age. It is compelling to note that this cost increased with HbA1c levels and BMI. Finally, the annual cost also increased with the number of complications."

According to the news editors, the research concluded: "The share and the cost of antihyperglycemic treatments vary with gender, age, type of health insurance coverage, HbA1c levels, BMI, and the number of complications."

For more information on this research see: Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany. Journal of Diabetes Science and Technology, 2016;11(1):123-127.

The news editors report that additional information may be obtained by contacting L. Jacob, 1 Dept. of Biology, Ecole Normale Superieure de Lyon, Lyon, France. Additional authors for this research include C. von Vultee and K. Kostev.

Keywords for this news article include: Lyon, France, Europe, Epidemiology, Endocrinology, Gender Health, Women's Health, Type 2 Diabetes, Health Insurance, Drugs and Therapies, Risk and Prevention, Glucose Metabolism Disorders, Non Insulin Dependent Diabetes Mellitus, Endocrine System Diseases and Conditions, Nutritional and Metabolic Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC